

Journal section: Oral Medicine and Pathology  
Publication Types: Research

doi:10.4317/medoral.22421  
<http://dx.doi.org/doi:10.4317/medoral.22421>

## Clinicopathological evaluation and survival of patients with squamous cell carcinoma of the tongue

Thamirys-Dantas Nóbrega <sup>1</sup>, Salomão-Israel-Monteiro-Lourenço Queiroz <sup>2</sup>, Edilmar-de Moura Santos <sup>3</sup>, Antônio-de Lisboa-Lopes Costa <sup>4</sup>, Leão Pereira-Pinto <sup>4</sup>, Lélia-Batista de Souza <sup>4</sup>

<sup>1</sup> Bolsista PIBIC-CNPq/Liga Norte Riograndense Contra o Câncer, Natal/RN Brasil

<sup>2</sup> Doutorando do programa de Pós-Graduação em Patologia Oral da Universidade Federal do Rio Grande do Norte, Natal/RN, Brasil

<sup>3</sup> Membro da Liga Norte Riograndense Contra o Câncer, Natal/RN Brasil

<sup>4</sup> Professor(a) do programa de Pós-Graduação em Patologia Oral da Universidade Federal do Rio Grande do Norte, Natal/RN, Brasil

### Correspondence:

Departamento de Odontologia – UFRN  
Disciplina de Patologia Oral  
Avenida Senador Salgado Filho  
1787 – Lagoa Nova  
CEP 59056-000 – Natal-RN  
[leliabsouza@gmail.com](mailto:leliabsouza@gmail.com)

Nóbrega TD, Queiroz SIML, Santos EM, Costa ALL, Pereira-Pinto L, de Souza LB. Clinicopathological evaluation and survival of patients with squamous cell carcinoma of the tongue. Med Oral Patol Oral Cir Bucal. 2018 Sep 1;23 (5):e579-87.  
<http://www.medicinaoral.com/medoralfree01/v23i5/medoralv23i5p579.pdf>

Received: 20/02/2018  
Accepted: 21/06/2018

Article Number: 22421 <http://www.medicinaoral.com/>  
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946  
eMail: [medicina@medicinaoral.com](mailto:medicina@medicinaoral.com)  
**Indexed in:**  
Science Citation Index Expanded  
Journal Citation Reports  
Index Medicus, MEDLINE, PubMed  
Scopus, Embase and Emcare  
Indice Médico Español

### Abstract

**Background:** Early detection of oral cancer is the most effective means of reducing morbidity, complexity, and extent of treatment. This study evaluated the clinicopathological profile of epidermoid carcinoma of the tongue, including treatment and survival.

**Material and Methods:** This observational, retrospective cross-sectional study evaluated patients with squamous cell carcinoma of the tongue treated at the Dr. Luiz Antônio Hospital, Natal, Brazil, from January 2001 to December 2011. Survival variables were calculated using the Kaplan-Meier method and compared by log rank tests. **Results:** Of the 412 patients diagnosed in this period, 298 (72.3%) were men; their mean age was 60.5 years, and 69.2% were diagnosed with stage III/IV tumours. Improved survival was associated with early stage diagnosis, absence of affected lymph nodes at diagnosis, and treatment with surgery alone.

**Conclusions:** Late stage diagnosis of oral cancer negatively affects patient survival. In addition, the general public should be made aware of the prognostic factors for oral SCC of the tongue and of the importance of periodic examinations of the oral cavity.

**Key words:** Mouth neoplasms, tongue neoplasms, carcinoma, squamous cell, survival analysis.

## Introduction

Cancer is a major cause of morbidity and mortality worldwide, with incidence rates varying widely depending on geographic location, age, sex and race (1). Low and middle income countries have proportionately higher cancer burdens than high income countries, but their health systems are unprepared to address this problem (2).

Oral squamous cell carcinoma (SCC) is the most common type of cancer affecting the oral mucosal epithelium (3). Its worldwide incidence is quite variable, being the main type of cancer in Southeast Asian countries. Cancer of the oral cavity is classified as a type of head and neck tumour. For Brazil, an estimated 11,200 new cases of oral cavity cancer in men and 3,500 in women are estimated for each year of the 2018-2019 biennium. These figures correspond to an estimated risk of 10.86 new cases per 100,000 men, ranking fifth; and 3.28 for every 100,000 women, being the 12th most frequent among all cancers (4).

The main risk factors for the development of SCC are the consumption of tobacco and alcohol and HPV infections, but only a fraction of these exposed people develop this neoplasia (5). These findings suggest that theory that genetic factors are individuals that contribute to greater susceptibility, differences in clinical behaviour and patient prognosis (5,6).

Although oral SCC can develop in various areas of the oral cavity, its highest incidence is in the tongue. Post-surgical recurrence rates are high, as is the propensity to develop regional lymph node metastases. Among patients with oral tumours, those with SCC of the tongue have the poorest survival rates (7,8).

Tumour aggressiveness has been associated with several factors, including the histological grade of malignancy, lesion size, the presence of metastases present at diagnosis and the anatomical location of the tumour (9). Treatment of these tumours, which can include surgery, radiotherapy and/or chemotherapy, depends largely on tumour location, clinical stage, histopathologic grading and the physical condition of the patient. The 5-year survival rate is about 50%, with no major changes in the past three decades, despite advances in treatment (10). Efforts are needed to evaluate the clinical and pathological parameters and diagnostic methods that can expedite the early detection of oral cancer and thus improve patient prognosis. This study therefore evaluated the clinicopathological characteristics of patients diagnosed with SCC of the tongue and treated at a single centre over an 11-year period, as well as evaluating the survival of these patients.

## Material and Methods

This retrospective, sectional study included patients histopathologically diagnosed with SCC of the tongue who were treated at Dr. Luiz Antonio Hospital, Na-

tal, Brazil, between January 2001 and December 2011. Patients were excluded if they had oral SCC at other sites or if their medical records did not report metastasis, recurrence and survival or if they only underwent incisional biopsy. Data collected from patients' medical records included sex; age; presence of lymph node metastasis, distant metastasis, or local recurrence; treatment; overall survival; and last record date or date of death. The study protocol was approved by the Research Ethics Committee of the Northern League Human Riograndense Against Cancer (CEP / LIGA (Approval No. 923192/2014), which waived the requirement for informed consent due to the retrospective nature of this study.

All data were analysed statistically using Stata / IC version 12.0 software (Stata Corp, College Station, TX). Survival variables were calculated using the Kaplan-Meier method and compared by log rank tests. Multivariate analysis of factors associated with survival was performed using the Cox stepwise regression model (hierarchical), from the highest to the lowest hazard ratio (HR). Variables selected to enter the model were those having a  $p$ -value  $\leq 0.250$  on log rank tests, a  $p$ -value  $> 0.05$  on proportionalities tests, with risk proportionalities graphs not touching. Models with a  $p$ -value  $\leq 0.05$  were considered statistically significant. Analysis of model waste by Sehoenfeld, Cox-Snell and residual score (DFBETA) tests showed that no individual patient result could interfere. Significant associations between clinicopathologic features and outcomes were evaluated using chi-square tests, with a  $p$ -value  $\leq 0.05$  considered statistically significant.

## Results

Of the 412 patients included in the study, 298 (72.3%) were men and 114 (27.7%) were women. Their mean age was  $60.5 \pm 14.1$  years (range, 19–100 years). Evaluation of educational level showed that 117 (28.4%) patients were illiterate and 189 (45.9%) had some schooling (primary, secondary or higher); information on the remaining 106 (25.7%) patients was not found in their medical records (Table 1, 1 continue).

Seventeen (4.12%) patients had more than one primary tumour, confirming that these tumours may be present at more than one anatomical site. In addition, 76 (18.45%) patients were diagnosed early, contributing to best survival.

Tobacco use and alcohol consumption were reported by 313 (76%) and 241 (58.5%) patients, respectively. Only 23 (5.6%) patients reported that they were never smokers and 76 (18.4%) stated that they did not consume alcohol. The male sex most associated with smoking ( $p = 0.005$ , 1.79 times more than women) and alcohol ( $p < 0.0001$ , 4.80 times more than women).

Analysis by type of treatment showed that 35 (8.5%) pa-

**Table 1.** Clinical and demographic data.

		n	%	% Valid	% Accumulated
T	T1	10	2,4	3,2	3,2
	T2	72	17,5	23,4	26,6
	T3	87	21,1	28,2	54,9
	T4	136	33,0	44,2	99,0
	TX	3	,7	1,0	100,0
	Total	308	74,8	100,0	
No information		104	25,2		
N	N0	125	30,3	40,6	40,6
	N1	63	15,3	20,5	61,0
	N2	75	18,2	24,4	85,4
	N3	35	8,5	11,4	96,8
	NX	10	2,4	3,2	100,0
	Total	308	74,8	100,0	
No information		104	25,2		
M	M0	219	53,2	71,1	71,1
	M1	8	1,9	2,6	73,7
	MX	81	19,7	26,3	100,0
	Total	308	74,8	100,0	
No information		104	25,2		
TNM	I	14	3,4	4,0	4,0
	II	54	13,1	15,3	19,3
	III	87	21,1	24,6	43,9
	IVA	157	38,1	44,5	88,4
	IVB	33	8,0	9,3	97,7
	IVC	8	1,9	2,3	100,0
	Total	353	85,7	100,0	
No information		59	14,3		
SEX	Male	298	72,3	72,3	72,3
	Female	114	27,7	27,7	100,0
IGE	0 - 60	212	51,5	51,5	51,5
	> 60	200	48,5	48,5	100,0

**Table 1 continue.** Clinical and demographic data.

		n	%	% Valid	% Accumulated
SCHOOLING	Illiterate	117	28,4	38,2	38,2
	Elementary School incomplete	119	28,9	38,9	77,1
	Elementary School complete	32	7,8	10,5	87,6
	High school	29	7,0	9,5	97,1
	Higher education	9	2,2	2,9	100,0
	Total	306	74,3	100,0	
No information		106	25,7		
DRINKING	Never	76	18,4	23,0	23,0
	Do not drink more	14	3,4	4,2	27,2
	Yes	241	58,5	72,8	100,0
	Total	331	80,3	100,0	
No information		81	19,7		
SMOKER	Never	23	5,6	6,4	6,4
	Ex-Smoker	24	5,8	6,7	13,1
	Yes	313	76,0	86,9	100,0
	Total	360	87,4	100,0	
No information		52	12,6		
TREATMENT	No	35	8,5	8,5	8,5
	Surgery	74	18,2	18,2	26,7
	Radiotherapy	34	8,3	8,3	35,0
	Chemotherapy	15	3,6	3,6	38,6
	Surgery and radiotherapy	44	10,7	10,7	49,3
	Chemo and radiation therapy	122	29,6	29,6	78,9
	Surgery, chemo and radiotherapy	87	21,1	21,1	100,0

tients did not undergo any kind of treatment (denial of the patient and terminal stages), 122 (29.6%) underwent chemotherapy and radiation therapy, and 131 (31.8%) underwent surgery and associated treatment. Of 123 patients, 74 (18.2%) underwent surgery alone, 34 (8.3%) received radiotherapy alone and 15 (3.6%) received chemotherapy alone.

Evaluation of TNM classification showed that 223 (54.1%) patients presented with local extension, including 87 (21.1%) classified as T3 and 136 (33%), as T4. Only 10 (2.4%) patients were classified as T1, indicat-

ing that few patients are diagnosed at an early stage of the disease. Information on T stage was not available for 59 (14.3%) patients. Assessment of regional spread (N), showed that 125 (30.3%) patients were classified as N0 and 110 (26.7%) as N2 and N3, with information not available for 104 (25.2%) patients. Evaluation of TNM classification showed that 68 (16.5%) were stage I or II and 285 (69.2%) were stage III or IV.

Of the 412 patients, 86 (20.8%) were censored and 224 (54.36%) died within five years. Median overall survival (OS) was 1.77 years (95% confidence interval [CI]

1.42–2.53 years). The 5-year OS rate was 42.61% (95% CI 37.56–47.56%) and remained stable thereafter (Fig. 1). The mean time of patients who died was 24.6 months. Twenty (8.92%) patients were monitored for  $\leq 0.1$  month, with the remainder followed-up for 0.1–96 months. Univariate analysis showed that factors associated with OS included T and N stage (TNM) and treatment (yes/no) (Table 2). Multivariate analysis using a Cox regression model showed that for only T stage (TNM) and

treatment (yes/no) were independent predictors of OS. Poorest survival outcomes were observed in patients with T3 and T4 tumours who did not undergo treatment (Table 3). Evaluation of the association between clinicopathological features and patient outcomes showed that smoking, treatment (yes/no), surgical treatment, chemotherapy and staging were significantly associated with survival ( $p < 0.05$  each).




Fig. 1. Survival function Kaplan-Meier.

**Table 2.** Univariate and proportionality assessment.

<b>Variables</b>		<b>Deaths</b>	<b>Survival (5 years)</b>	<b>HR</b>	<b>CI 95%</b>	<b>P (Log Rank)</b>
<b>Sex</b>	<b>Female</b>	55	49,46	1		
	<b>Male</b>	169	39,83	1,274	1,121-1,468	0,047
<b>Age</b>	<b>&gt; 60 years</b>	103	45,62	1		
	<b>0-60 years</b>	121	39,89	1,099	0,832-1,090	0,485
<b>T</b>	<b>T1 and T2</b>	28	64,92	1		
	<b>T3 and T4</b>	160	25,61	3,058	2,044-4,574	<0,001
<b>N</b>	<b>N-</b>	59	50,52	1		
	<b>N+</b>	124	26,12	2,096	1,535-2,861	<0,001
<b>M</b>	<b>M-</b>	120	43,24	1		
	<b>M+</b>	7	12,50	2,024	0,943-4,343	0,064
<b>Staging</b>	<b>I and II</b>	17	74,36	1		
	<b>III and IV</b>	186	31,65	3,743	2,274-6,155	<0,001
<b>Habit Drink</b>	<b>No</b>	47	46,60	1		
	<b>Yes</b>	151	33,94	1,305	0,940-1,810	0,109
<b>Habit Smoke</b>	<b>No</b>	19	58,54	1		
	<b>Yes</b>	186	38,11	1,592	0,992-2,553	0,049
<b>Treatment</b>	<b>Yes</b>	192	46,09	1		
	<b>No</b>	32	4,35	7,712	5,211-11,411	<0,001
<b>Surgery</b>	<b>Yes</b>	70	62,49	1		
	<b>No</b>	154	23,55	1,711	1,612-1,882	<0,001
<b>Radiotherapy</b>	<b>No</b>	56	53,81	1		
	<b>Yes</b>	168	38,90	1,030	0,761-1,395	0,845
<b>Chemotherapy</b>	<b>No</b>	84	52,55	1		
	<b>Yes</b>	140	35,36	1,230	0,938-1,613	0,133

HR: Hazard Ratio; CI 95%: Confidence Interval of 95%.

**Table 3.** Multivariate analysis with adjusted Cox regression.

Variables		HR	HR adjusted	CI 95%	<i>p</i>
Tratament	Yes	1	1		
	No	7,712	10,775	8,102-20,654	<0,001
TNM	T1 and T2	1	1		
	T3 and T4	3,743	3,331	1,919-5,784	<0,001
Habit Smoke	No	1	1		
	Yes	1,305	1,344	0,801-2,53	0,262
Habit Drink	No	1	1		
	Yes	1,592	1,034	0,685-1,561	0,872
Sex	Female	1	1		
	Male	1,274	1,061	0,729-1,542	0,756

HR: Hazard Ratio; CI 95%: Confidence Interval of 95%.

## Discussion

The incidence and mortality rates from oral cancer are high in various populations. Moreover, oral cancer can have a negative effect on patient quality of life, causing problems in swallowing and speaking, as well as significant facial disfigurements that can lead to serious problems in patients' social lives (2).

SCC of the tongue is the most common cancer of the oral cavity, accounting for 25% to 40% of affected patients. The tongue has a rich lymphatic network and muscle structure, making the tongue the site most often associated with cervical metastases from tumours at other sites in the mouth, resulting in poor patient prognosis (12).

The main risk factors associated with oral SCC of the tongue are genetic predisposition, immune system suppression, nutritional deficiencies, and exposure to the carcinogenic effects of smoking and alcohol consumption (6). These factors can have a synergistic effect, with the incidence of oral SCC of the tongue being directly proportional to the amount and duration of exposure. Other factors as solar radiation exposure and viruses infections, including human papilloma virus (HPV) which are more specific of other SCC, respectively the lip and oropharynx (1,5,11). The majority of studies of oral SCC found that all reported alcohol consumption and/or smoking tobacco (10-18).

Treatment of oral SCC of the tongue usually includes surgery and/or radiation therapy and/or chemotherapy.

Few malignancies at present are treated with only one modality. Multidisciplinary care, integrating cancer services (surgery, radiotherapy and chemotherapy) with each other and general services is therefore important (4).

Surgery and radiation therapy have shown favourable results in the treatment of early lesions, with outcomes depending on tumour location and functional changes caused by treatment. Although the cure of early lesions is about 80%, about 10–20% of early lesions, especially those located on the tongue and/or mouth floor, may have subclinical spread to the cervical lymph nodes. These patients may require a combination of surgery and radiotherapy (4). Patients with more advanced tumours, who are not candidates for surgery, are frequently treated with combinations of chemotherapy and radiotherapy. These patients generally have an extremely poor prognosis, because of the inability to fully control these more extensive lesions (4). Observed fact in the service evaluated in this study.

To determine the most effective clinical approach, it is necessary to evaluate factors significantly prognostic of survival. Factors found to have a significant negative effect on patient survival include age >60 years, lesion in the tongue, thickness of the primary tumour between T3 and T4 and clinical TNM stage III or IV (13-17).

Tongue SCC occurs primarily in men aged  $\geq 60$  years (10,14-17). Similarly, our study of 412 patients with

tongue SCC treated at the Hospital Dr. Luiz Antônio, Natal, Brazil, found that 72.3% of patients with tongue SCC were male, probably because are more exposed to risk factors, including alcohol and tobacco consumption, both of which are more common habits in men than in women ( $p < 0,05$ ).

Similar to previous findings (14-17), the patients in our study were of mean age  $60.5 \pm 14.1$  years (range, 19–100 years), with 51.0% aged 0–60 years (50.96%). The highest prevalence by decade was in patients aged 50–59 years (26.21%), in agreement with earlier results (8).

Patient prognosis is improved if oral SCC of the tongue is identified at an early stage. At this stage, however, patients have few or no symptoms, with this absence contributing to delayed diagnosis and treatment (10). For this reason the clinical signs are important for the early diagnosis, so any alteration in the oral cavity that persists for 15 days or more, seek a dental surgeon for evaluation. The self-examination done by the patient may also help in this early diagnosis (3,4).

Treatment is dependent the tumour site, disease stage and general patient health. An earlier diagnosis will require less aggressive treatment, resulting in better function and aesthetic outcomes (8,9). One study reported better overall survival in patients undergoing surgery alone than other forms of therapy (10). In contrast, the 5-year overall survival rate in patients treated with different therapeutic modalities was reaching 24% (10).

According to the Almeida (13) classification, the main factors influencing patient prognosis and survival include the size and location of the primary tumour, regional lymph node involvement, and the presence of distant metastases, with all of these factors included in TNM stage. Prognosis is significantly better in patients with stage I than stage IV tumors (10,18). This study found that tumour size (T stage) and the presence of lymph nodes at diagnosis (N stage) were significant predictors of patient outcomes. This finding indicates that T and N stages can be considered independent factors prognostic of overall survival in this group of patients and that patients without lymph node metastases at initial diagnosis and with T1 or T2 tumours have a higher survival rate (64.92%), confirming previous results (10,18).

After analysing the high mortality rates evidenced in this study and the published reports, it can be concluded that this is a serious disease because of the difficulties of access to adequate treatment, medical professionals often not able to make the appropriate initial diagnosis, and neglect of patients not seeking care but having habits that trigger the disease, corroborating with several surveys (10-18).

Therefore, it is not enough to treat the cancer, but it is also necessary to improve access to health care for the population and raise awareness about the risk fac-

tors associated with this disease and related illnesses and train professionals to undertake the diagnosis right. Early detection is the best way to ensure the survival of a cancer patient. It can represent efficacy in the treatment until the patient cures, being one of the main findings of this research.

This study evaluated the clinical and pathological parameters associated with improved survival in patients with oral SCC of the tongue. The absence of lymph node metastases at diagnosis and smaller tumour size were predictive of better survival. Campaigns and projects to encourage and promote the early diagnosis of cancer among health professionals are necessary. In addition, the general public should be aware of the risk factors and prognostic factors for oral SCC of the tongue and of the importance of periodic examinations of the oral cavity.

## References

1. Torres-Pereira CC, Angelim-Dias A, Melo NS, Lemos CA Jr, Oliveira EMF. Strategies for management of oral cancer in primary and secondary healthcare services. *Cad Saude Publica*. 2012;28 Suppl:S30-S9.
2. Barbosa IR, Costa ICC, Pérez MMB, de Souza DLB. As inequidades sociais e as disparidades na mortalidade por câncer relativo ao gênero. *Rev Ciênc Plur*. 2015;1:79–86.
3. Jadhav KB, Gupta N. Clinicopathological prognostic implicators of oral squamous cell carcinoma: need to understand and revise. *N Am J Med Sci*. 2013;5(6):671–9.
4. INSTITUTO NACIONAL DO CANCER (INCA). Mouth Cancer, Available: <http://www.inca.gov.br/estimativa/2018/sintese-de-resultados-comentarios.asp> (Accessed March 5, 2018).
5. Andrews E, Seaman WT, Webster-Cyriaque J. Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. *Oral Oncol* 2009; 45(6): 486–91.
6. Bagan JV, Scully C. Recent advances in Oral Oncology 2008: squamous cell carcinoma aetiopathogenesis and experimental studies. *Oral Oncol*. 2009;45:e45–8.
7. Le Campion ACOV, Ribeiro CMB, Luiz RR, da Silva Júnior FF, Barros HCS, Dos Santos KCB et al. Low Survival Rates of Oral and Oropharyngeal Squamous Cell Carcinoma. *Int J Dent*. 2017;2017:5815493.
8. Antunes AA, Antunes AP, Silva PV, Avelar RL, Santos TS. Tongue cancer: retrospective study of twenty years. *Rev Bras Cir Cabeça Pescoço*. 2007;36:152–4.
9. Brandizzi D, Gandolfo M, Velasco ML, Cabrini RL, Lanfranchi HE. Clinical features and evolution of oral cancer: a study of 274 cases in Buenos Aires, Argentina. *Med Oral Patol Oral Cir Bucal* 2008; 13(9): 544–8.
10. Honorato J, Camisasca DR, da Silva LE, Dias FL, de Faria PAS, Lourenço SQ. Overall survival analysis in oral squamous cell carcinoma patients diagnosed at the National Cancer Institute in 1999. *Rev Bras Epidemiol*. 2009;12:69–81.
11. Martins JD, Andrade JOM, Freitas VS, Araújo TM. Social determinants of health and the occurrence of oral cancer: a systematic literature review. *Rev Saude Publica*. 2014;16:786–98.
12. Süslü Nİ, Hoşal AŞ, Aslan T, Sözeri B, Dolgun A. Carcinoma of the oral tongue: a case series analysis of prognostic factors and surgical outcomes. *J Oral Maxillofac Surg*. 2013;71:1283–90.
13. Almeida FCSA, Casal C, Nunes FD, Araujo ME, Dias RB, Silva DP. Prognostic factors in oral cancer. *Rev Bras Cienc Saúde*. 2011;15:471–8.
14. Murthy V, Agarwal JP, Laskar SG, Gupta T, Budrukkar A, Pai P, et al. Analysis of prognostic factors in 1180 patients with oral cavity primary cancer treated with definitive or adjuvant radiotherapy. *J Cancer Res Ther*. 2010;6:282–9.



15. Vasconcelos MG, Mafra RP, Vasconcelos RG, de Medeiros AMC, Queiroz LMG. Squamous cell carcinoma of the tongue: clinical and morphological analysis of 57 cases and correlation with prognosis. *J Bras Patol Med Lab.* 2014;50:359–63.
16. Mani C, Lakshminarayana G, Kurian A, Annapurneshwari. Predictors of recurrence in early stage oral tongue squamous cell carcinoma. *J Orofac Sci.* 2015;7:86–9.
17. Gupta K, Panda NK, Bakshi J, Das A. To evaluate disparity between clinical and pathological tumor-node-metastasis staging in oral cavity squamous cell carcinoma patients and its impact on overall survival: An institutional study. *South Asian J Cancer.* 2015;4:183–5.
18. Banipal R, Mahajan MK, George G, Sachdev J, Jeyaraj P. Carcinoma base of tongue: Single institution 15 year experiences. *Indian J Cancer.* 2012;49:220–4.

***Conflicts of interest***

No conflicts.